DOSAGE AND ADMINISTRATION

For Intravenous Use Only

**Indication** | **Dose** | **Initial infusion rate** | **Maintenance infusion rate** (if tolerated)
--- | --- | --- | ---
**PI** | 300-800 mg/kg (3-8 mL/kg) every 3-4 weeks | 0.5 mg/kg/min (0.005 mL/kg/min) for 15 minutes and increase gradually every 15 minutes to 8 mg/kg/min (0.08 mL/kg/min) | 
**ITP** | 1 g/kg (10 mL/kg) for 2 consecutive days | 0.5 mg/kg/min (0.005 mL/kg/min) for 15 minutes and increase gradually every 15 minutes to 8 mg/kg/min (0.08 mL/kg/min) |

**INDICATIONS AND USAGE**

**GAMMAPLEX 10%** is an Immune Globulin Intravenous (Human) 10%. Liquid immunoglobulin products are used to treat primary humoral immunodeficiency (PI) and chronic immune thrombocytopenic purpura (ITP) in adults.

**DOSAGE FORMS AND STRENGTHS**

GAMMAPLEX 10% is a liquid solution containing 10% IgG (100 mg/mL).

**CONTRAINDICATIONS**

- Hypersensitivity to components of GAMMAPLEX 10%
- Acute renal failure
- Hemolysis
- Aseptic meningitis syndrome
- Volume overload

**WARNINGS AND PRECAUTIONS**

- IgA-deficient patients with antibodies to IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions.
- Hyperproteinemia, increased serum viscosity, and hyponatremia may occur in patients receiving GAMMAPLEX 10%.
- Aseptic meningitis syndrome may occur, especially with high doses or rapid infusion.
- Hemolysis, either intravascular or due to enhanced red blood cell sequestration, can develop subsequent to GAMMAPLEX 10% treatments. Risk factors include high doses and non-O blood group.
- Closely monitor patients for hemolysis and hemolytic anemia.
- Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury (TRALI))
- Volume overload can occur. Monitor for signs and symptoms.
- Consider risks and benefits before prescribing the high dose regimen for chronic ITP in patients at risk of thrombosis.
- GAMMAPLEX 10% is made from human plasma and may contain infectious agents, e.g. viruses and, theoretically, the Creutzfeldt-Jakob disease agent.
- Passive transfer of antibodies may confound serologic testing.

**ADVERSE REACTIONS**

- **PI** - The most common adverse reactions reported in >5% of adult clinical trial subjects were headache, migraine, and pyrexia.
- **Chronic ITP** - The safety of GAMMAPLEX 10% has not been established in patients with ITP. However, the safety of GAMMAPLEX 5% has been studied in subjects with ITP and it is anticipated that the safety profile for both formulations are comparable for ITP patients. Hence adverse reaction information is presented for GAMMAPLEX 5% where relevant. The most common adverse reactions reported with GAMMAPLEX 5% in >5% of clinical trial subjects with ITP were headache, vomiting, nausea, pyrexia, arthralgia, and dehydration.

**DRUG INTERACTIONS**

- Passive transfer of antibodies may transiently interfere with the immune response to live virus vaccines, e.g. measles, mumps, and rubella.
- Therapy with GAMMAPLEX 10% may confound serological testing.

**USE IN SPECIFIC POPULATIONS**

- **Pregnancy**: No human or animal data. Use only if clearly indicated.
- **Geriatrics**: In patients over the age of 65 years or in any patient at risk of developing renal insufficiency, do not exceed the recommended dose and infusion rate.

See 17 for Patient Counseling Information.
**1 INDICATIONS AND USAGE**

1.1 Primary Humoral Immunodeficiency (PI) – GAMMAPLEX 10% is an Immune Globulin Intravenous (Human), 10% Liquid indicated for replacement therapy in primary humoral immunodeficiency (PI) in adults. This includes, but is not limited to, the humoral immune defect in common variable immunodeficiency, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott–Aldrich syndrome, and severe combined immunodeficiencies.

1.2 Chronic Immune Thrombocytopenic Purpura (ITP) – GAMMAPLEX 10% is indicated for the treatment of chronic immune thrombocytopenic purpura (ITP) in adults to raise platelet counts. For intravenous use only.

**2 DOSAGE AND ADMINISTRATION**

2.1 Dosage

For Intravenous Use Only

**2.2 Preparation and Handling**

- For administration of large doses, pool multiple vials using aseptic technique
- Infuse GAMMAPLEX 10% using a separate infusion line
- Do not mix GAMMAPLEX 10% with other intravenous medications (including normal saline) or other IGIV products
- Do not use any solution that has been frozen
- Administer GAMMAPLEX 10% at room temperature (up to 25°C [77°F])
- Do not use solution that has been frozen [see How Supplied/ Storage and Handling (16)]
- Use aseptic technique
- Student vials for single use only. Dispose of partially used or unused product
- Infuse GAMMAPLEX 10% intravenously using an intravenous infusion set. See Table 1 for recommended infusion rates
- Monitor vital signs throughout the infusion
- Slow or stop the infusion if adverse reactions occur
- If symptoms subside, the infusion may be resumed at a lower rate that is comfortable for the patient
- The observation time of patients after GAMMAPLEX 10% administration may vary. If the patient (a) has not received GAMMAPLEX 10% or another IgG product, (b) is switched from an alternative IgG product or (c) has had a long interval since the previous infusion, prolong the observation time for adverse reactions after GAMMAPLEX 10% infusion
- Certain severe adverse reactions may be related to the rate of infusion. Slowing or stopping the infusion often allows the reaction to disappear
- Ensure that patients with pre-existing renal insufficiency are not volume depleted
- For patients at increased risk of renal dysfunction, thrombotic events, or volume overload, administer GAMMAPLEX 10% at the minimum infusion rate practicable. Consider discontinuing GAMMAPLEX 10% administration if renal function deteriorates (see Boxed Warning, Warnings and Precautions (5.1, 5.2, 5.8))

2.3 Administration

- Infuse GAMMAPLEX 10% as a single intravenous infusion
- Do not administer the medication within 30 minutes after combining it with other intravenous medications
- Do not use GAMMAPLEX 10% in a syringe shared among patients
- The observation time for adverse reactions after GAMMAPLEX 10% infusion
- The observation time of patients after GAMMAPLEX 10% administration may vary. If the patient (a) has not received GAMMAPLEX 10% or another IgG product, (b) is switched from an alternative IgG product or (c) has had a long interval since the previous infusion, prolong the observation time for adverse reactions after GAMMAPLEX 10% infusion
- Certain severe adverse reactions may be related to the rate of infusion. Slowing or stopping the infusion often allows the reaction to disappear
- Ensure that patients with pre-existing renal insufficiency are not volume depleted
- For patients at increased risk of renal dysfunction, thrombotic events, or volume overload, administer GAMMAPLEX 10% at the minimum infusion rate practicable. Consider discontinuing GAMMAPLEX 10% administration if renal function deteriorates (see Boxed Warning, Warnings and Precautions (5.1, 5.2, 5.8))

**3 DOSAGE FORMS AND STRENGTHS**

GAMMAPLEX 10% is a liquid solution containing 10% IgG (100 mg/mL).

**4 CONTRAINDICATIONS**

- GAMMAPLEX 10% is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin
- GAMMAPLEX 10% is contraindicated in IgA-deficient patients with antibodies to IgA and a history of hypersensitivity

**5 WARNINGS AND PRECAUTIONS**

5.1 Renal Dysfunction/Failure

- Acute renal dysfunction/failure, acute renal failure, and death may occur upon use of human IGIV products. Ensure that patients are not volume depleted before administering GAMMAPLEX 10%. In patients who are at risk of developing renal dysfunction, because of pre-existing renal insufficiency, predisposition to acute renal failure (such as diabetes mellitus, hypovolemia, overweight, use of concomitant nephrotoxic medicinal products or age >65 years), administer GAMMAPLEX 10% at the minimum infusion rate practicable (see Dosage and Administration (2.3)).

Periodic monitoring of renal function and urine output is particularly important in patients judged to be at increased risk of developing acute renal failure. Assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of GAMMAPLEX 10% and at appropriate intervals thereafter. If renal function deteriorates, consider discontinuing GAMMAPLEX 10%.

**FULL PRESCRIBING INFORMATION**

**WARNING: THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE**

- Thrombosis may occur with immune globulin products, including GAMMAPLEX 10%. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors [see Warnings and Precautions (5.1)].

- Thrombosis may occur in the absence of known risk factors [see Warnings and Precautions (5.1)].

- Thrombosis may occur in the absence of known risk factors [see Warnings and Precautions (5.1)].

- Thrombosis may occur in the absence of known risk factors [see Warnings and Precautions (5.1)].
5.2 Hemolytic Events
Thrombosis may occur following treatment with immune globulin products, including GAMMAPLEX 10%. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hypercoagulability and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.

Consider baseline assessment of blood viscosity in patients at risk for hypercoagulability, including those with cryoglobulins, fasting chylomicronemia/markedly high triglycerides (triglycerides), or monoclonal gammopathies. For patients at risk of thrombosis, administer GAMMAPLEX 10% at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before treatment. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hypercoagulability (see Boxed Warning, Dosage and Administration (2.3), Patient Counseling Information (17)).

5.3 Hypersensitivity
Severe hypersensitivity reactions may occur (see Contraindications (4)). In case of hypersensitivity, discontinue GAMMAPLEX 10% infusion immediately and institute appropriate treatment. Medications such as epinephrine should be available for immediate treatment of acute hypersensitivity reactions.

GAMMAPLEX 10% contains trace amounts of IgG (<20 micrograms/mL) (see Description (11)). Patients with known antibodies to IgG may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. GAMMAPLEX 10% is contraindicated in patients with antibodies against IgG and a history of hypersensitivity reaction (see Contraindications (4)).

5.4 Hyperproteinemia, Increased Serum Viscosity, and Hyponatremia
Hyperproteinemia, increased serum viscosity, and hyponatremia may occur in patients receiving IGIV therapy. It is critical to clinically distinguish true hyponatremia from a pseudohyponatremia that is associated with or causally related to hyperproteinemia with concomitant decreased calculated serum osmolality or elevated osmolar gap, because treatment aimed at decreasing serum free water in patients with pseudohyponatremia may lead to volume depletion, a further increase in serum viscosity, and a possible predisposition to thromboembolic events.

5.5 Aseptic Meningitis Syndrome (AMS)
AMS may occur with IGIV treatment. AMS usually begins within several hours to 2 days following IGIV treatment. Discontinuation of IGIV treatment has resulted in resolution of AMS within several days without sequelae.

AMS is characterized by the following signs and symptoms: severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea, and vomiting (see Patient Counseling Information (17)). Cerebrospinal fluid (CSF) studies frequently reveal pleocytosis up to several thousands of cells per cubic millimeter, predominantly from the granulocytic series, and elevated protein levels up to several hundred mg/dL but negative culture results. Conduct a thorough neurological examination on patients exhibiting such signs and symptoms, including CSF studies, for AMS.

5.6 Hemolysis
GAMMAPLEX 10% may contain blood group antibodies that can act as hemolysins and induce in vivo coating of red blood cells (RBCs) with immunoglobulin, causing a positive direct antiglobulin test (DAT) (Coombs’ test) result and hemolysis. Delayed hemolytic anemia can develop subsequent to IGIV therapy due to enhanced RBC sequestration; acute hemolysis, consistent with intravascular hemolysis, has been reported. Cases of severe hemolysis-related renal dysfunction/failure or disseminated intravascular coagulation have occurred following infusion of IGIV.

The following risk factors may be associated with the development of hemolysis following IGIV administration: high doses (e.g., ≥2 g/kg), given either as a single administration or divided over several days, and non-O blood group. Other individual patient factors, such as an underlying inflammatory state (as may be reflected by, for example, elevated C-reactive protein or erythrocyte sedimentation rate), have been hypothesized to increase the risk of hemolysis following administration of IGIV, but their role is uncertain. Hemolysis has been reported following administration of IGIV for a variety of indications, including ITP and PP.

Closely monitor patients for clinical signs and symptoms of hemolysis, particularly patients with risk factors noted above. Consider appropriate laboratory testing in higher risk patients, including measurement of hemoglobin or hematocrit prior to infusion and within approximately 36 to 96 hours post infusion. If clinical signs and symptoms of hemolysis or a significant drop in hemoglobin or hematocrit have been observed, perform confirmatory laboratory testing. If transfusion is indicated for patients who develop hemolysis with clinically compromising anemia after receiving IGIV, perform adequate cross-matching to avoid exacerbating on-going hemolysis.

5.7 Transfusion-related Acute Lung Injury (TRALI)
Noncardiogenic pulmonary edema may occur in patients following IGIV treatment. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxia, normal left ventricular function and fever. Symptoms typically appear within 1 to 6 hours following treatment.

Monitor patients for pulmonary adverse reactions. If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies in both the product and the patient’s serum.

TRALI may be managed using oxygen therapy with adequate ventilatory support.

5.8 Volume Overload
Carefully consider the relative risks and benefits before prescribing the high dose regimen (for chronic ITP) in patients at increased risk of volume overload.

5.9 Transmissible Infectious Agents
As GAMMAPLEX 10% is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases or CJD have been associated with the use of GAMMAPLEX 10%. All infections suspected by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare providers to BPL Inc. 1-844-427-5872 or MedInfo@BPL-US.com.

Before prescribing GAMMAPLEX 10%, the physician should discuss the risks and benefits of its use with the patient (see Patient Counseling Information (17)).

5.10 Laboratory Tests
• After infusion of immunoglobulin, the transitory rise of the various passively transferred antibodies in the patient’s blood may yield positive serological testing results, with the potential for misleading interpretation
• Passive transmission of antibodies to erythrocyte antigens (e.g., A, B, and D) may cause a positive direct or indirect antiglobulin (Coombs’) test
• Clinically assess patients with known renal dysfunction, diabetes mellitus, age greater than 65 years, volume depletion, sepsis, paraproteinemia, or those receiving nephrotoxic agents, and monitor as appropriate (BUN, serum creatinine, urine output) during therapy with GAMMAPLEX 10%
• Consider baseline assessment of blood viscosity in patients at risk for hypercoagulability, including those with polycythemia, chylomicronemia, fasting chylomicronemia/markedly high triglycerides, or monoclonal gammopathies
• Consider measuring hemoglobin or hematocrit at baseline and approximately 36 to 96 hours post infusion in patients at higher risk of hemolysis.

If signs and/or symptoms of hemolysis are present after an infusion of GAMMAPLEX 10%, perform appropriate laboratory testing for confirmation
• If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies in both the product and patient’s serum

6 ADVERSE REACTIONS
The safety information for GAMMAPLEX 10% is based on the clinical trial evaluating the bioequivalence of GAMMAPLEX 10% to GAMMAPLEX 5% in subjects with PI. The safety of GAMMAPLEX 10% has not been established in patients with ITP. However, the safety profile for GAMMAPLEX 5% has been studied in subjects with ITP, and it is anticipated that the safety profile for both formulations are comparable for ITP patients. Hence adverse reactions (ARs) information is presented for GAMMAPLEX 5% where relevant. ARs are adverse events that were deemed by the investigators as causally related to GAMMAPLEX 10%. Thrombotic Events (see Warnings and Precautions (5.21))

5.6 Hemolysis

The following potential serious ARs are described above and elsewhere in the labeling:
• Thrombotic Events
• Hemolysis (see Warnings and Precautions (5.6))
6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Primary Humoral Immunodeficiency Study

A multicenter, open-label, randomized two-period crossover study (bioequivalence study) evaluated the PK, safety and tolerability of GAMMAPLEX 10% and GAMMAPLEX 5% in 33 adults aged 17 to 55 years with PI. Twenty one (63.6%) subjects were female and 12 (36.4%) were male; 33 (100%) were White [32 (97.0%) were not Hispanic or Latino and 1 (3.0%) was Hispanic or Latino]. The safety analysis included all 33 subjects for GAMMAPLEX 5% and 32 subjects for GAMMAPLEX 10%. One subject withdrew consent during the first infusion of GAMMAPLEX 5%, citing inconvenience of the study visits. Thirty two subjects received at least five infusions of each product either on a 28-day or 21-day cycle. The mean doses per infusion for GAMMAPLEX 5% were 491.7 mg/kg and 499 mg/kg respectively, and were similar for GAMMAPLEX 5% [see Clinical Studies (14.1)]. No subjects were on regular systemic corticosteroids at entry to, or during the study. Twelve (36.4%) adult subjects received short courses of corticosteroids, from 1 to 5 days, for a maximum of 6 days duration, for various clinical conditions. No subjects received corticosteroids as premedications for GAMMAPLEX infusions. The use of local anesthetics, antipyretics, antihistamines, and antinfectives before infusion was allowed; three (9.1%) adult subjects received a total of 5 courses of such premedication.

While on GAMMAPLEX 5%, 10 of the adults (31.3%) had an adverse reaction (AR) with a similar proportion (12; 36.4%) when on GAMMAPLEX 5%. Headache was the most commonly reported AR with both formulations of GAMMAPLEX. Table 2 lists the ARs occurring in ≥5% of adult subjects receiving GAMMAPLEX 10% in the study. In total, 166 infusions of GAMMAPLEX 10% and 163 infusions of GAMMAPLEX 5% were given during the study.

Table 2: Adverse Reactions (ARs*) Occurring in ≥5% of Adult Subjects Receiving GAMMAPLEX 10%

<table>
<thead>
<tr>
<th>Preferred Term</th>
<th>Subjects (%) (n=32)</th>
<th>Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>12 (37.5)</td>
<td>12</td>
</tr>
<tr>
<td>Migraine</td>
<td>2 (6.3)</td>
<td>2</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>2 (6.3)</td>
<td>2</td>
</tr>
</tbody>
</table>

*Adverse Reactions (ARs) are defined as adverse events considered by the investigators to have been possibly, probably, or definitely related to administration of GAMMAPLEX.

Two subjects had a positive direct antiglobulin (Coombs’) test (DAT; DCT) result at some stage in the study. For one adult, the test was positive before starting in the study and it remained positive throughout, but without evidence of hemolysis. One other adult had a positive DAT one week after an infusion of GAMMAPLEX 5% but there was no evidence of hemolysis and no positive DAT results when receiving GAMMAPLEX 10%. No other adults had a positive DAT during the study.

Chronic Immune Thrombocytopenic Purpura Study

The safety of GAMMAPLEX 10% has not been established in patients with ITP. However, the safety profile for GAMMAPLEX 5% has been studied in subjects with ITP, and it is anticipated that the safety profile for both formulations are comparable for ITP patients. The following is a summary of the ARs experienced with GAMMAPLEX 5% in chronic ITP. In a multicenter, open-label, non-randomized clinical trial, 35 subjects with chronic ITP were treated with a nominal dose of 1000 mg/kg on each of two consecutive days (total dose 2000 mg/kg). Doses of GAMMAPLEX 5% ranged from 482 to 1149 mg/kg on an infusion day. The median total dose per subject was 2035 mg/kg. Pre-medication with antihistamine or analgesic drugs was permitted if required, but corticosteroids were not permitted prior to infusion as pre-medication. Ten subjects received corticosteroids for ITP during the trial and one additional subject received corticosteroids as pre-medication in violation of the protocol. All 35 subjects received at least one infusion of clinical trial drug, and all but one subject completed the first course of treatment.

Fifteen subjects (42.9%) reported at least one AR (63 in total); the most commonly reported being headache (10 subjects, 28.6%), vomiting (6 subjects, 17.1%), nausea (3 subjects, 8.6%), pyrexia (5 subjects, 14.5%), arthralgia (2 subjects, 5.7%) and dehydration (2 subjects, 5.7%). Three subjects experienced a total of five serious ARs. Of the five serious ARs, one subject had three concurrently (vomiting, dehydration and headache) and two subjects each had one serious AR (headache). One of these latter two subjects discontinued from the clinical trial because of the severe headache. Table 3 lists the ARs in more than ≥5% of data.

Based on a review of clinical and laboratory data, 4/35 subjects (11%) with drops in hemoglobin exceeding 2 g/dL following administration of GAMMAPLEX 5% were considered to have experienced suspected treatment-emergent hemolysis. Milder treatment-emergent hemolysis could not be excluded for an additional 7 subjects, giving a total of 11 of 35 subjects (31%) for whom hemolysis could not be excluded (not including an additional two subjects who lacked follow-up testing for hemolysis, so their hemolysis status was considered unassessable). Data for two subjects were consistent with possible intravascular hemolysis, including one subject who may also have had an element of extravascular hemolysis. None of the possible hemolysis cases were mild and appeared consistent with possible extravascular hemolysis. There was no evidence of transmission of HBV, HCV, HIV and parvovirus B19 during this clinical trial.

Table 3: Adverse Reactions (ARs*) Occurring in ≥5% of Subjects with ITP

<table>
<thead>
<tr>
<th>Adverse Reactions</th>
<th>Subjects % (n=35)</th>
<th>Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>10 (28.6)</td>
<td>19</td>
</tr>
<tr>
<td>Vomiting</td>
<td>6 (17.1)</td>
<td>8</td>
</tr>
<tr>
<td>Nausea</td>
<td>3 (8.6)</td>
<td>3</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>5 (14.3)</td>
<td>6</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>2 (5.7)</td>
<td>2</td>
</tr>
<tr>
<td>Dehydration</td>
<td>2 (5.7)</td>
<td>2</td>
</tr>
</tbody>
</table>

*Adverse Reactions (ARs) are defined as adverse events considered by the investigators to have been possibly, probably, or definitely related to administration of GAMMAPLEX.

6.2 Postmarketing Experience

Because adverse reactions are voluntarily reported post-approval from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to product exposure.

There is no postmarketing experience with GAMMAPLEX 10%; the following adverse reactions have been identified during postmarketing use of GAMMAPLEX 5% [see also Adverse Reactions (6.1)].

In the postmarketing experience, there have been no deaths or cases of permanent organ dysfunction or injury attributable to the administration of GAMMAPLEX. GAMMAPLEX infusions have been given to at least five patients who had no evidence of hemolysis and no positive DAT results when receiving GAMMAPLEX 10%. No other adverse reactions have been identified during postmarketing use of intravenous immune globulins.

The following adverse reactions have been identified during postmarketing use of intravenous immune globulins:

- Infusion reactions: hypotension, bradycardia, fever, rigors, back pain, myalgia, arthralgia, headache, generalized erythema, changes in blood pressure
- Renal: Acute renal dysfunction/failure, osmotic nephropathy
- Respiratory: Apnea, Acute Respiratory Distress Syndrome (ARDS), TRALI, cyanosis, hypoxemia, pulmonary edema, dyspnea, bronchospasm
- Cardiovascular: Cardiac arrest, thromboembolism, vascular collapse, hypotension
- Neurological: Coma, loss of consciousness, seizures, tremor, aseptic meningitis syndrome
- Integumentary: Rash, urticaria
- Musculoskeletal: Myalgia, arthralgia

The following adverse reactions have been identified during postmarketing use of intravenous immune globulins:

- Hematopoietic: Pancytopenia, leukopenia, thrombocytopenia, positive direct antiglobulin (Coombs’) test
- Gastrointestinal: Hepatic dysfunction, abdominal pain
- General/Body as a Whole: Pyrexia, rigors

No subjects
7 DRUG INTERACTIONS

- Transitory rise of the various passively transferred antibodies in the patient’s blood after infusion of immunoglobulin may yield positive serological testing results, with the potential for misleading interpretation. Passive transmission of antibodies to erythrocyte antigens (e.g., A, B, and D) may cause a positive direct or indirect antiglobulin (Coombs') test
- Passive transfer of antibodies may transiently interfere with the immune response to live virus vaccines such as measles, mumps, rubella and varicella.12 13 Inform the immunizing physician of recent therapy with GAMMAPLEX 10% so that appropriate measures may be taken [see Patient Counseling Information (17)].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Animal reproduction studies have not been conducted with GAMMAPLEX 10%. It is also not known whether GAMMAPLEX 10% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. GAMMAPLEX 10% should be given to a pregnant woman only if clearly needed.12

8.2 Lactation

Risk Summary

Use of GAMMAPLEX 10% has not been evaluated in breast-feeding mothers.

8.4 Pediatric Use

Treatment of Primary Humoral Immunodeficiency

The safety and effectiveness of GAMMAPLEX 10% has not been established in pediatric patients with PI [see Clinical Studies (14)].

Treatment of Chronic Immune Thrombocytopenic Purpura

The safety and effectiveness of GAMMAPLEX 10% has not been established in pediatric patients with ITP. GAMMAPLEX 5% was evaluated in three (3) pediatric subjects with chronic ITP (two aged 6 years and one aged 12 years). This number of pediatric patients was too small for separate evaluation from the adult patients for efficacy [see Clinical Studies (14)].

8.5 Geriatric Use

Use caution when administering GAMMAPLEX 10% to patients aged 65 years and over who are judged to be at increased risk of developing renal insufficiency or thrombotic events [see Boxed Warning, Warnings and Precautions (5.1, 5.2)]. Do not exceed recommended doses, and administer GAMMAPLEX 10% at the minimum infusion rate practicable.

No subjects over the age of 55 years were included in the clinical study of GAMMAPLEX 10%. Eight (8) patients with PI at or over the age of 65 years were included within the clinical evaluation of GAMMAPLEX 5%. The number of geriatric patients was too small for separate evaluation from the younger patients for safety or efficacy [see Clinical Studies (14)].

10 OVERDOSAGE

Overdosage may lead to fluid overload and hyperviscosity, particularly in the elderly and in patients with renal impairment.

11 DESCRIPTION

GAMMAPLEX 10% is a sterile solution of polyclonal human Immunoglobulin G for intravenous administration that contains glycine and polysorbate 80 as stabilizers. Specifically, GAMMAPLEX contains approximately 10 g normal human immunoglobulin and 200–300 mM glycine in 100 mL of buffer solution containing: <30 mM acetate, <30 mM sodium chloride and 1–6 mg polysorbate 80. Immunoglobulin G purity is ≥98%, the pH is in the range of 4.9 to 5.2, and osmolality is not less than 240 mOsmol/kg (typically 280 mOsmol/kg). The distribution of the four IgG subclasses reflects that of normal plasma. The content of IgA is less than 20 micrograms/mL. The anti-D and anti-A/anti-B hemagglutinin content of the drug product is strictly controlled to specification.

GAMMAPLEX 10% contains no reducing carbohydrate stabilizers (e.g., sucrose, maltose) and no preservative.

GAMMAPLEX 10% is manufactured from large pools of human plasma by a combination of cold ethanol fractionation and ion exchange chromatography. Fab functions tested include antigen binding activity, and Fc functions tested include complement activation and rubella antibody-mediated hemolysis.

GAMMAPLEX 10% is manufactured from plasma, obtained from healthy US donors, who have passed viral screening tests. All donors are subjected to medical examinations, laboratory tests, and a review of their medical history before being allowed to donate blood or plasma.

All plasma donations are screened for antibody to HIV-1/2 and hepatitis C virus (HCV), and hepatitis B surface antigen (HBsAg). Additional testing of donations is carried out in plasma mini-pools (512 donations per pool) that undergo nucleic acid amplification testing (NAT) for HIV, hepatitis B virus (HBV), HCV, hepatitis A virus (HAV) and parvovirus B19. Further testing is carried out on the manufacturing pools for HBsAg, and antibody to HIV-1/2, HCV and parvovirus B19 are also tested by NAT, with the limit for B19 set to not exceed 10 IU B19 DNA per mL plasma.

There are three processing steps specifically designed to remove or inactivate viruses:

1) Solvent/Detergent treatment is targeted to enveloped viruses;
2) A virus filtration step designed to remove small viruses including non-enveloped viruses, on a size exclusion basis; and
3) The terminal low pH incubation step is identified as contributing to the overall viral clearance capacity for enveloped and non-enveloped viruses.

The capacity of the manufacturing process to remove and/or inactivate enveloped and non-enveloped viruses has been validated by laboratory spiking studies on a scaled down process model. Overall virus reduction was calculated only from steps that were mechanistically independent from each other.

In addition, each step was validated to provide robust virus reduction. Table 5 presents the contribution of each process step to virus reduction and the overall process reduction.
Table 5: Viral Reduction by Process Step

<table>
<thead>
<tr>
<th>Virus</th>
<th>Type (Envelope/Genome)</th>
<th>Size (nm)</th>
<th>Process Log&lt;sub&gt;c&lt;/sub&gt;, Reduction of Virus (LRV) over manufacturing step</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV</td>
<td>Env/RNA</td>
<td>80-100</td>
<td>&gt;6.8, 1, 6.0, &gt;12.8</td>
</tr>
<tr>
<td>SIN</td>
<td>Env/RNA</td>
<td>70</td>
<td>&gt;6.7, 0.2, &gt;5.4, NT, &gt;8.8</td>
</tr>
<tr>
<td>WNV</td>
<td>Env/RNA</td>
<td>50</td>
<td>&gt;6.4, 1, NT, &gt;6.4</td>
</tr>
<tr>
<td>BDV</td>
<td>Env/DNA</td>
<td>40-50</td>
<td>&gt;5.5, 1, &gt;4.0, &gt;5.6</td>
</tr>
<tr>
<td>IBR</td>
<td>Env/DNA</td>
<td>200</td>
<td>&gt;5.0, 1, &gt;5.4, &gt;10.4</td>
</tr>
<tr>
<td>HAV</td>
<td>Non-Env/RNA</td>
<td>30</td>
<td>NT, &gt;4.8, 1.5, &gt;6.3</td>
</tr>
<tr>
<td>EMC</td>
<td>Non-Env/RNA</td>
<td>30</td>
<td>NT, &gt;4.8, 3.4, &gt;8.2</td>
</tr>
<tr>
<td>CPV</td>
<td>Non-Env/RNA</td>
<td>18-24</td>
<td>NT, 3.2, 1.0, 4.2</td>
</tr>
</tbody>
</table>

HIV: Human immunodeficiency virus  
SIN: Sindbis virus, model for hepatitis C virus (HCV)  
WNV: West Nile Virus  
BDV: Bovine viral diarrhea virus, model for HCV  
IBR: Infectious bovine rhinotracheitis, bovine herpes virus model for enveloped DNA viruses including hepatitis B  
HAV: Hepatitis A virus  
EMC: Encephalomyocarditis, model for HAV  
CPV: Canine parvovirus, model for human parvovirus B19  
NA: Not applicable, solvent detergent step is limited to the inactivation of enveloped viruses  
I: Inactivation by the product intermediate precluded the accurate estimation of the removal of these viruses by the filtration step  
NT: Not tested  
B19: Viral clearance of human parvovirus B19 was investigated experimentally at the 20 nm filtration step. The estimated Log reduction Factor obtained was 6.0

12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Treatment of Primary Humoral Immunodeficiency
GAMMAPLEX 10% is a replacement therapy for primary humoral immunodeficiency. GAMMAPLEX 10% acts through a broad spectrum of opsonic and neutralizing IgG antibodies against pathogens and their toxins involving antigen binding and effector functions. However, the mechanism of action in PI has not been fully elucidated.  

12.3 Pharmacokinetics
Treatment of Primary Humoral Immunodeficiency
In the cross-over clinical trial assessing bioequivalence, safety and tolerability between GAMMAPLEX 10% and GAMMAPLEX 5% in PI, the pharmacokinetics (PK) of these products was assessed after administration to 30 adult subjects on 28-day (n = 16) or 21-day (n = 14) infusion cycles. Blood samples for PK analysis were obtained after at least five infusions.  
The dose of GAMMAPLEX 10% ranged from 361-691 mg/kg for subjects on a 28-day cycle and from 254-794 mg/kg for those on a 21-day cycle. The doses of GAMMAPLEX 5% were similar to those of GAMMAPLEX 10% in this cross-over study. Table 6 compares the other PK variables for GAMMAPLEX 10% and GAMMAPLEX 5% for both the 21-day and 28-day cycle regimens.  
GAMMAPLEX 10% was pharmacokinetically equivalent to GAMMAPLEX 5% in adults.

Table 6: Pharmacokinetic Parameters of GAMMAPLEX 10% compared with GAMMAPLEX 5% in Adults (corrected for baseline concentration)

<table>
<thead>
<tr>
<th>Parameter (unit)</th>
<th>GAMMAPLEX 10%</th>
<th>GAMMAPLEX 5%</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>28-day Dosing Interval</td>
<td>21-day Dosing Interval</td>
</tr>
<tr>
<td></td>
<td>(n=16)</td>
<td>(n=14)</td>
</tr>
<tr>
<td>Mean&lt;sup&gt;3&lt;/sup&gt; (CV%)</td>
<td>1090 (20.5)</td>
<td>1150 (27.6)</td>
</tr>
<tr>
<td>T&lt;sub&gt;max&lt;/sub&gt; (hr)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>2.87 (1.6-31)</td>
<td>2.70 (1.8-7.8)</td>
</tr>
<tr>
<td>AUC&lt;sup&gt;4&lt;/sup&gt; (mg*day/L)</td>
<td>7830 (30.2)</td>
<td>6580 (33.0)</td>
</tr>
<tr>
<td>Half-Life (hr)</td>
<td>123 (32.3)</td>
<td>118 (39.3)</td>
</tr>
<tr>
<td>Clearance (mL/day/kg)</td>
<td>0.0635 (24.0)</td>
<td>0.0674 (21.9)</td>
</tr>
<tr>
<td>Volume of Distribution (L/kg)</td>
<td>0.498 (27.4)</td>
<td>0.528 (50.3)</td>
</tr>
</tbody>
</table>

<sup>1</sup>AUC<sub>tau→0</sub> = area under the concentration versus time curve within a dosing interval, tau = dosing interval  
<sup>2</sup>C<sub>max</sub> = maximum observed concentration  
<sup>3</sup>T<sub>max</sub> = time at which C<sub>max</sub> was apparent  
<sup>4</sup>Median and range are presented for T<sub>max</sub>  
<sup>5</sup>Geometric mean
14 CLINICAL STUDIES

14.1 Treatment of Primary Humoral Immunodeficiency

Pharmacokinetics, Safety and Tolerability study

A cross-over clinical trial assessed bioequivalence, safety and tolerability between GAMMAPLEX 10% and GAMMAPLEX 5% in PI after administration to 32 adult subjects on 28-day (n = 19) or 21-day (n = 14) infusion cycles, of whom 30 (90.0%) completed the PK component. See Pharmacokinetics (22.3.2). Thirty-two subjects completed the study of whom 12 were male and 20 were female. All adults were aged between 17 and 55 years. The mean doses of GAMMAPLEX 10% were 491.7 mg/kg for those on a 28-day cycle and 499.0 mg/kg for those on a 21-day cycle. For GAMMAPLEX 5%, the doses were similar: 473.5 and 502.1 mg/kg respectively. The maximum infusion rate was 0.08 ml/kg/min for each product and this rate was achieved by all adult subjects. In this study, PK bioequivalence was used as a surrogate marker for efficacy. Nevertheless, an ad hoc comparison was made between the products for the number of subjects reporting an infection while on each product. Comparing the number of subjects developing infections of any severity or type while on GAMMAPLEX 10% (22/32) with the period on GAMMAPLEX 5% (17/32) using the McNemar test provided an exact p value of 0.180, confirming the relevance of PK as a surrogate marker. No subject had an acute serious bacterial infection (SAB) during the study.

14.2 Treatment of Chronic Immune Thrombocytopenic Purpura

The crossover bioequivalence study described in 14.1, above, did not include subjects with ITP. The results of the bioequivalence study comparing GAMMAPLEX 10% to GAMMAPLEX 5% in subjects with PI are supportive of the potential effectiveness of GAMMAPLEX 10% in the treatment of chronic ITP.

In a Phase 3 multicenter, open-label clinical trial to evaluate the efficacy and safety of GAMMAPLEX 5% in chronic ITP, of the 35 subjects enrolled from various ethnic groups, 9 were male and 26 were female. The age range was between 6 and 69 years. Subjects received intravenous infusions on two consecutive days (1 course) and then observed for a further 30 days. Individuals were given the option of a further two courses of treatment (if required), where only safety variables were assessed. Doses of GAMMAPLEX 5% ranged from 482 to 1149 mg/kg on Day 1 and Day 2. The median total dose per subject was 2035 mg/kg. Subjects received a total of 94 infusions (48 treatment courses). All 35 subjects received at least one infusion of clinical trial drug, and all but one subject completed the first course of treatment.

The primary analysis was based on the platelet count achieved by Day 9 after the first course of treatment with GAMMAPLEX 5%, response being defined as a platelet count of 50 x 10^9/L or greater. Response to treatment on or before Day 9 was achieved by 29 of 35 subjects (82.9%), and the one-sided 97.5% lower confidence limit of the response rate was 68.4%, which met the a priori success criterion that required it to be greater than 60%.

Efficacy analyses included the duration of response, and changes in the incidences of bleeding or hemorrhage. At Day 32, the median (+ SD) platelet count (24 + (90) x 10^9/L) was still higher than the baseline value, and 11 of 33 subjects (33.3%) continued to show response of platelet counts of 50 x 10^9/L or greater. The median duration of platelet count response for the responders was 10 days.

Table 7: Median Platelet Count (Standard deviation) and Number and Percent of Subjects with a Platelet Count > 50 x 10^9/L during the clinical trial.

<table>
<thead>
<tr>
<th>Number of days in clinical trial</th>
<th>Day 9</th>
<th>Day 14</th>
<th>Day 21</th>
<th>Day 32</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median Platelet count (x 10^9/L) (Std Dev)</td>
<td>120 (11.4)</td>
<td>50.0 (36.4)</td>
<td>33.0 (79.3)</td>
<td>121.5 (151.9)</td>
</tr>
<tr>
<td>Number of subjects with a platelet count &gt; 50 x 10^9/L</td>
<td>18/35 (51.4%)</td>
<td>22/32 (68.8%)</td>
<td>20/32 (62.5%)</td>
<td>11/33 (33.3%)</td>
</tr>
</tbody>
</table>

GAMMAPLEX 5% infusions given on Days 1 and 2.

There was an increase in platelet counts for the majority of subjects, and an overall reduction in the manifestations of bleeding after treatment compared to baseline (Day 1). Petechiae, hematomas and gastrointestinal, pulmonary and genitourinary bleeds were all either reduced or absent by Day 32.

There were no thromboembolic episodes reported in the clinical trial, and vital signs, biochemical, hematological and virology tests did not reveal any unexpected pathophysiology or toxicity.

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING

GAMMAPLEX is supplied in a single use, clear Type II glass bottle, closed with a stopper and oversealed with a tamper-evident cap. The components used in the packaging for GAMMAPLEX 10% are latex free.

The following presentations of GAMMAPLEX 10% are available:

<table>
<thead>
<tr>
<th>Grams and Fill Size</th>
<th>Carton NDC Number</th>
<th>Vial NDC Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 g in 50 mL</td>
<td>64208-8235-5</td>
<td>64208-8235-1</td>
</tr>
<tr>
<td>10 g in 100 mL</td>
<td>64208-8235-6</td>
<td>64208-8235-2</td>
</tr>
<tr>
<td>20 g in 200 mL</td>
<td>64208-8235-7</td>
<td>64208-8235-3</td>
</tr>
</tbody>
</table>

Each vial has a label with a peel-off strip showing the product name and batch number. When stored between 2 °C [35.6 °F] and 25 °C [77 °F], GAMMAPLEX 10% has a shelf-life of 36 months. Keep GAMMAPLEX 10% in its original carton to protect it from light. Do not shake. Do not use GAMMAPLEX 10% beyond the expiration date on the product label. Do not freeze.

17 PATIENT COUNSELING INFORMATION

Inform patients to immediately report the following signs and symptoms to their healthcare professional:

- Decreased urine output, sudden weight gain, fluid retention/edema, and/or shortness of breath [see Warnings and Precautions (5.1)]
- Acute chest pain, shortness of breath, leg pain, and swelling of the legs/feet [see Warnings and Precautions (5.2)]
- Severe headache, neck stiffness, drowsiness, fever, sensitivity to light, painful eye movements, nausea and vomiting [see Warnings and Precautions (5.5)]
- Increased heart rate, fatigue, yellowing of skin or eyes, dark-colored urine [see Warnings and Precautions (5.6)]
- Trouble breathing, chest pain, blue lips or extremities, fever [see Warnings and Precautions (5.7)]

Inform patients that GAMMAPLEX 10% is made from human plasma and may contain infectious agents that can cause disease. While the risk that GAMMAPLEX 10% can transmit an infection has been reduced by screening plasma donors for prior exposure, testing donated plasma, and inactivating or removing certain viruses during manufacturing, patients should report any symptoms that concern them [see Warnings and Precautions (5.9)].

Inform patients that GAMMAPLEX 10% can interfere with their immune response to live viral vaccines (e.g. measles, mumps, and rubella), and instruct patients to notify their healthcare professional of this potential interaction when they are receiving vaccinations [see Drug Interactions (7)].

Instruct patients to immediately report symptoms of thrombosis. These symptoms may include: pain and/or swelling of an arm or leg with warmth over the affected area, discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid pulse, numbness or weakness on one side of the body.

Manufactured by:
Bio Products Laboratory Ltd.,
Elstree,
WD6 3BX.
United Kingdom.
US License No. 1811

U.S. Distributor:
BPL Inc.,
302 E. Pettigrew Street,
Suite C-190,
Durham, NC 27701,
U.S.A.